Kevin Jones currently serves as SVP for Business Development and Commercialization for Micelle. Dr. Jones has over 25 years experience in healthcare, initially developing some of the first rapid diagnostic tests designed for field use, before moving into the commercialization of novel technology for multinational healthcare providers. In this role he has managed all aspects of the technology pipeline, and successfully launched regulated products in four continents. In addition to his technical experience he has been responsible for establishing sales and support networks, for both direct sales and distributor based relationships globally. Dr. Jones is a regular presenter at international conferences, and as well as being an experienced manager and has successfully founded or cofounded four companies in both the US and EU.
Harvey Rubinson currently serves as Chief Financial Officer for Micelle BioPharma. He has extensive experience as a senior manager in multiple industries, both domestic and international, involving company restructuring, operational improvement, and increasing revenue and profits. Formerly a managing director with AlexPartners, LLP and XRoads Solutions Group, Rubinson worked with companies in a revenue range from $15 to $800 million as interim CFO, COO, or operational improvement advisor. The companies included Neff Rental (Miami), Bally Total Fitness (Chicago), Pabst Brewing (San Antonio), and Wackenhut Corporation, now G4S (Palm Beach Gardens). He currently holds a Certified Turnaround Professional designation from the Turnaround Management Association.
Dr. Sampson is currently the Chief Medical Officer for Micelle BioPharma, Inc. He is a cardiologist and trained physician-scientist with an understanding of the bigger picture of healthcare in addition to broad expertise, management skills, and leadership experience. He is a Professor of Population Health (Adjunct) at New York University School of Medicine. He served as a Branch Chief at the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH). His role supported and fostered healthcare service delivery innovation by developing initiatives to improve our understanding of the health system levers that can be modulated to improve multi-level (patient, provider, and health system) outcomes. During his tenure at the NIH/NHLBI, Dr. Sampson received 4 NHLBI Director’s Awards for his leadership activities. In addition to research or clinical fellowships at Oxford University, Harvard Medical School, and Vanderbilt University, Dr. Sampson had training and experience in various facets of clinical trials, outcomes research, and healthcare organization and administration via graduate programs in Public Health, Business Administration, Evidence-Based Health Care, and biostatistics. He served on the clinical endpoints committee of two landmark cardiovascular clinical trials: Candesartan in Heart Failure (CHARM) and VALsartan In Acute myocardial iNfarcTion (VALIANT) trials. Dr. Sampson’s career development was supported by the Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation, the Vanderbilt Clinical and Translational Scholars Award, the American College of Cardiology Foundation/General Electric Career Development Award, and the Future Leaders in Cardiovascular Medical Research Award from Merck/Schering-Plough administered by the Leadership Council for Improving Cardiovascular Care.